4 recruiting, 2 terminated, 2 withdrawn, 1 completed. 11 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Recruiting 4, Terminated 2, Withdrawn 2, Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 5 | Recruiting 2, Completed 1, Not yet recruiting 1, Terminated 1 |
Follow Relapsed Acute Myeloid Leukemia: new trials by email Literature Review of Relapsed Acute Myeloid Leukemia trials Research Report on Relapsed Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML Tagraxofusp, Cladribine (CLAD), Cytarabine - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | Stanford University | 20 | 2025-02-10 | 2026-04-14 |
| Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML Decitabine, Azacitidine, Mitoxantrone liposome, Cytarabine, G-CSF - AML, Relapsed Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 20 | 2024-10-31 | 2024-12-27 |
| VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Recruiting | Beijing 302 Hospital | 67 | 2024-07-18 | 2024-08-05 |
| Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML Cytokine induced memory-like NK cells, Fludarabine, Ara-C - Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2023-06-30 | 2023-04-04 | |
| A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) Lanraplenib, Gilteritinib - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | Kronos Bio | 24 | 2022-08-05 | 2024-08-07 |
| Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS Cytokine-induced memory-like NK cells, Fludarabine, Cyclophosphamide - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Withdrawn | Washington University School of Medicine | 2022-06-30 | 2022-03-11 | |
| Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia Venetoclax, Decitabine, Azacytidine, Cytarabine - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Unknown | Beijing 302 Hospital | 52 | 2022-05-01 | 2022-05-05 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-04-17 |
| Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Flotetuzumab, Donor lymphocyte infusion - Relapsed Acute Myeloid Leukemia | Phase 2 | Terminated | Washington University School of Medicine | 11 | 2021-05-20 | 2024-12-06 |
| Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia Pembrolizumab, Decitabine - Relapsed Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2016-12-16 | 2022-12-28 |
Leukemia, Myeloid, Acute (11) · Myelodysplastic Syndromes (2) · Neoplasm, Residual (2) · Burkitt Lymphoma (1) · Leukemia, Biphenotypic, Acute (1) · Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1) · Sarcoma, Myeloid (1)
Hematologic Diseases (11) · Hemic and Lymphatic Diseases (11) · Leukemia (11) · Leukemia, Myeloid (11) · Neoplasms by Histologic Type (11) · Neoplasms (10) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Bone Marrow Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplastic Processes (2)
Cytarabine (5) · Azacitidine (4) · Decitabine (4) · venetoclax (3) · Cladribine (2) · Granulocyte Colony-Stimulating Factor (2) · Interleukin-2 (2) · fludarabine (2) · Cyclophosphamide (1) · Dexamethasone (1) · Filgrastim (1) · Immune Checkpoint Inhibitors (1) · Inotuzumab Ozogamicin (1) · Leukapheresis (1) · Mitoxantrone (1)
Beijing 302 Hospital (3) · Washington University School of Medicine (3) · BeOne Medicines (1) · Kronos Bio (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Stanford University (1) · University of Washington (1)
United States (5) · China (2) · Spain (1)
Amanda Cashen, M.D. (1) · Christopher S Hourigan, M.D. (1) · Jeffrey Bednarski, M.D., Ph.D. (1) · Mary-Beth M. Percival (1) · Matthew Christopher, M.D., Ph.D. (1) · Xiao-ning Gao (1)
P50CA171963 (1)